TY - JOUR
T1 - Lymphoid Reconstruction and Vaccines
AU - Gress, Ronald E.
AU - Komanduri, Krishna V.
AU - Einsele, Hermann
AU - Cooper, Laurence J.N.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/1
Y1 - 2007/1
N2 - Allogeneic HSCT is the most reliable, robust, and effective cell-based biotherapy currently available to pediatric and adult patients with hematologic malignancies. The central role of donor-derived lymphocytes in mediating an effective antitumor effect, preventing and controlling opportunistic infections, and causing GVHD is well documented in animal experiments and human trials. The profound lymphopenia after conditioning regimens coupled with molecular tools to distinguish host versus donor cells provides investigators a window into immune recovery after allogeneic HSCT. Serial analyses of T cell subsets linking immunophenotype with function have revealed the kinetics of donor-derived T cell recovery after allografting and provided insights into ways the immune system can be manipulated to augment the graft-versus-tumor (GVT) effect without inducing GVHD. As this review demonstrates, investigators are not limited to being passive observers of this immune reconstitution; rather, we have an opportunity to shape the allografted T cells repertoire to selectively augment immune function.
AB - Allogeneic HSCT is the most reliable, robust, and effective cell-based biotherapy currently available to pediatric and adult patients with hematologic malignancies. The central role of donor-derived lymphocytes in mediating an effective antitumor effect, preventing and controlling opportunistic infections, and causing GVHD is well documented in animal experiments and human trials. The profound lymphopenia after conditioning regimens coupled with molecular tools to distinguish host versus donor cells provides investigators a window into immune recovery after allogeneic HSCT. Serial analyses of T cell subsets linking immunophenotype with function have revealed the kinetics of donor-derived T cell recovery after allografting and provided insights into ways the immune system can be manipulated to augment the graft-versus-tumor (GVT) effect without inducing GVHD. As this review demonstrates, investigators are not limited to being passive observers of this immune reconstitution; rather, we have an opportunity to shape the allografted T cells repertoire to selectively augment immune function.
KW - Adoptive immunotherapy
KW - Hematopoietic stem cell transplantation
KW - Immune reconstitution
KW - Lymphodepletion
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=33846017305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846017305&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2006.10.012
DO - 10.1016/j.bbmt.2006.10.012
M3 - Article
C2 - 17222765
AN - SCOPUS:33846017305
VL - 13
SP - 17
EP - 22
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - SUPPL. 1
ER -